<DOC>
	<DOCNO>NCT00959621</DOCNO>
	<brief_summary>1 % pregnancy end habitual/recurrent abortion . In half woman habitual abortion ( HAB ) hereditary acquire ( antiphospholipid antibody ) thrombophilia observe . The investigator want test whether antithrombotic treatment ( Low-Molecular Weight Heparin , LMWH , ASA combine ) would prevent woman subsequent abortion . Depending thrombophilic status woman include one three sub-studies : HABENOX 1 ( mild , single thrombophilia ) , HABENOX 2 ( know thrombophilia ) , HABENOX 3 ( moderate severe thrombophilia , combine thrombophilia moderate high titer antiphospholipid antibody ) . Study design : Randomised placebo control multicenter study . Number patient per study : 90 patient per group , 270 altogether . Timetable : Starting 2/2002 , finish 31.12.2007 . Time frame : &gt; 37 week gestation &gt; 24 , &lt; 37 week gestation ( premature ) Treatment start 7. gw . HABENOX 1 2 : Study group : Group 1 : Enoxaparin 40 mg+ placebo , Group 2 : Enoxaparin 40 +ASA 100 mg , Group 3 : ASA . HABENOX 3 : Study group : Group 1 : Enoxaparin 40 twice daily+ placebo o.d. , Group 2 : Enoxaparin 40 mg twice daily +ASA 100 mg o.d . Primary end-points : Pregnancy outcome : livebirths ( ≥37 week gestation ) , premature livebirths ( ≥24 , &lt; 37 week gestation ) Secondary end-points : Bleeding complication , intrauterine growth retardation ( &lt; -2SD ) , pre-eclampsia , abruptio placenta , Ending : In group combine medication , tablet stop 36 week gesta-tion . LMWH start patient delivery continue 6 week postpartum .</brief_summary>
	<brief_title>Low Molecular Weight Heparin and/or Aspirin Prevention Habitual Abortion</brief_title>
	<detailed_description>Background : The prevalence spontaneous abortion 1000-1500/10000 pregnancy per year mean 10-15 % pregnancy end abortion ; 1/10 abortion recurrent ( 1 % pregnancy ) . In half woman habitual abortion ( HAB ) hereditary ( F V Leiden , F II ( prothrombin ) mutation , Protein C , S deficiency anti-thrombin ) acquire ( antiphospholipid antibody ) thrombophilia observe . Efficacy medical treatment patient history HAB yet completely demonstrate . We recently show low-molecular-weight heparin ( LMWH ) effective unfractionated heparin prevention thromboembolic complication pregnant woman cause less bleeding complication ( UFH ) osteoporotic effect . LMWH could safer UF-heparin long treatment period ( 7-8 month ) . Study design : Randomised placebo control multicenter study . Centers : Helsinki ( 2 ) , Oulu ( 1 ) , Stockholm ( 1 ) , Leiden ( 1 ) Number patient per study : 90 patient per group , 270 altogether Timetable : Starting 2/2002 , finish 31.12.2007 Drugs : HABENOX 1 2 : Study group Group 1 : Enoxaparin 40 mg+ placebo , Group 2 : Enoxaparin 40 +ASA 100 mg , Group 3 : ASA . HABENOX 3 : Study group Group 1 : Enoxaparin 40 twice daily+ placebo o.d. , Group 2 : Enoxaparin 40 mg twice daily +ASA 100 mg o.d . Time frame : one year since enter study primary end-points : livebirths ( &gt; 37 week gestation ) premature livebirths ( &gt; 24 , &lt; 37 week gestation ) Primary end-points : Pregnancy outcome : livebirths ( &gt; 37 week gestation ) , premature livebirths ( &gt; 24 , &lt; 37 week gestation ) Secondary end-points : Bleeding complication , intrauterine growth retardation ( &lt; -2SD ) , pre-eclampsia , abruptio placenta , Inclusion criterion : Three consecutive abortion first trimester ( ad h 12+6 wks ) two second trimester abortion ( ad h 13 wks-23+6 wks ) one third trimester abortion ( 24 week ) one first-second trimester abortion . Depending thrombophiliatest ( tested pregnancy ) result patient include one three sub-studies : 1 . HABENOX 1 : one thrombophiliatest positive : F V Leiden ( heterozygote ) protein C S deficiency , anticardiolipin antibody ( low moderate level ) , prothrombin gene mutation , high level F VIII . 2 . HABENOX 2 : thrombophilia test negative 3 . HABENOX 3 : `` high risk '' thrombophilia : positive combine thrombophilia , F V Leiden ( homozygote ) , anticardiolipin antibody ( high level &gt; 40 ) , lupusanticoagulant , AT III deficiency . During next pregnancy patient , inclusion criterion fulfil , ask sign inform consent allocate one three treatment group . The treatment start 7 week gestation . At baseline follow-up visit plasma , serum 20 ml morning urine frozen ( analyse later antithrombin , protein S , C , APC ratio , PAI1 , PAI2 , U-PAR , D-dimer , thrombin-antithrombin ( TAT ) complex , CRP , TNFalpha ( + receptor ) , ICAM , VEGF ( +receptor ) , urinary stabile metabolite thromboxane prostacyclin . Follow-up : US/Doppler + obstetric check-up 8 , 10 , 14 , 18 , 24 , 28 , 32 36 week gestation Ending : In group combine medication , tablet stop 36 week gesta-tion . LMWH start patient delivery continue 6 week postpartum .</detailed_description>
	<mesh_term>Abortion , Habitual</mesh_term>
	<mesh_term>Aspirin</mesh_term>
	<mesh_term>Heparin , Low-Molecular-Weight</mesh_term>
	<mesh_term>Dalteparin</mesh_term>
	<mesh_term>Heparin</mesh_term>
	<criteria>Habenox 1 : Three consecutive abortion first trimester ( ad h 12+6 wks ) two second trimester abortion ( ad h 13 wks23+6 wks ) one third trimester abortion ( 24 week ) one firstsecond trimester abortion one thrombophiliatest positive : F V Leiden ( heterozygote ) protein C S deficiency , anticardiolipin antibody ( low moderate level ) , prothrombin gene mutation , high level F VIII . HABENOX 2 : The thrombophilic test negative . HABENOX 3 : positive combine thrombophilia , F V Leiden ( homozygote ) , anticardiolipin antibody ( high level &gt; 40 ) , lupusanticoagulant , AT III deficiency . History DVT pulmonary embolism . Significant bleeding history .</criteria>
	<gender>Female</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2009</verification_date>
	<keyword>Habitual abortion</keyword>
	<keyword>recurrent abortion</keyword>
	<keyword>hereditary acquire</keyword>
	<keyword>thrombophilia</keyword>
	<keyword>preeclampsia</keyword>
	<keyword>premature birth</keyword>
	<keyword>miscarriage</keyword>
	<keyword>stillbirth</keyword>
	<keyword>LMWH ( low molecular weigh heparin )</keyword>
	<keyword>ASA</keyword>
	<keyword>aspirin</keyword>
</DOC>